This pilot early phase I trial studies how well metformin hydrochloride works in reducing metabolic activity of cancer cells in patients with head and neck squamous cell cancer. Metformin hydrochloride may alter markers of metabolism in head and neck cancer cells and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02083692.
PRIMARY OBJECTIVES:
I. Assess the impact of metformin (metformin hydrochloride) on translocase of outer mitochondrial membrane 20 homolog (TOMM20) expression by immunohistochemistry (IHC) in squamous carcinoma cells and the impact of metformin on monocarboxylate transporter 4 (MCT4) expression in fibroblasts.
SECONDARY OBJECTIVES:
I. Assess safety and tolerability of metformin treatment in subjects with head and neck cancer.
II. To assess the potential impact of metformin on the following: progression free survival, overall survival, objective response rate, duration of response, frequency of metastasis, and staging.
OUTLINE: This is a dose-escalation study.
Patients receive metformin hydrochloride orally (PO) once daily for 3 days, twice daily (BID) for 3 days, and then BID until the day prior to their scheduled definitive surgery, for a minimum of 9 days and a maximum of 5 weeks.
After completion of study treatment, patients are followed up at 30 days and then every 3 months for 2 years.
Lead OrganizationThomas Jefferson University Hospital
Principal InvestigatorJoseph Mathias Curry